From the Wires
U.S. Patent and Trademark Office Issues Patent 8,212,658, Fifth in Portfolio Protecting Technology to Advance Medication Management
New Directions Technology Consulting, LLC, Is Exclusive mHealth-Market Developer for the mMed Patent Portfolio for Mobile Medication Management
By: Marketwire .
Nov. 29, 2012 09:32 AM
HUNTINGTON, NY -- (Marketwire) -- 11/29/12 -- U.S. Patent 8,212,658, the fifth in a portfolio of patents protecting technology that could significantly advance medication management, has been issued by the USPTO. New Directions Technology Consulting, LLC (New Directions) is the exclusive market developer of the intellectual property.
New Directions Managing Director Napoleon Monroe, the inventor on all patents in what is called the mMed portfolio for mobile medication management, brings his decades of experience in manufacturing, licensing, regulatory process and risk management to the effort.
"Optimum management of chronic and acute health problems that require medication therapy depends on patients following instructions for treatment prescribed by medical professionals -- what's called 'adherence,'" said Monroe. "But patient nonadherence impedes wellness and drives up to $300 billion of avoidable U.S. healthcare costs, with costs of related lost productivity arguably even greater."
Monroe continued: "As the world's mobile-communications user community grows, new 'smart' tools, such as in the patent claims, can be developed to help patients themselves successfully manage medication therapies outside institutional settings."
He noted that advanced mobile medication management systems using technology protected by the mMed patent portfolio could include:
Such systems could not only give "a critical boost to medication adherence," but also could provide "additional benefits to all stakeholders" in the healthcare supply chain: patients, caregivers, employers, insurers, government and taxpayers, said Monroe. When at Survival Technology (now part of Pfizer), Monroe invented three medical devices that were patented and commercialized, and led teams that invented, prototyped, tested, commercialized and/or scaled up such products as the EpiPen and the Antidote Treatment Nerve Agent Auto-Injector delivery system.
In addition to providing reminders and facilitating the replenishment process, systems based on technology protected by the mMed patent portfolio could do much more, Monroe said, including:
mMed Patent Portfolio
Through New Directions, business opportunities related to the mMed patent portfolio include: licensing of patents or the entire portfolio, licensing for specific disease conditions or geographies, or partnering to develop tools, platforms or systems based on the patents. The U.S. portfolio of granted patents includes:
U.S. Patent No. 7,752,085 (issued 7/6/2010): Product Information Management System
Monroe said: "Greater patient autonomy through technology can result in better health outcomes and reduced costs. Providing medication management tools to patients also presents tremendous business opportunities for those at the forefront of the evolving mHealth industry."
About New Directions Technology Consulting, LLC
For more information about the mMed patent portfolio, please go to www.mmedhealth.com.
Note: mMed is a trademark of New Directions Technology Consulting, LLC. Any other names of actual companies, organizations, entities, products or services may be the trademarks of their respective owners.
Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=2167245
SOA World Latest Stories
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
SYS-CON Featured Whitepapers
Most Read This Week